UK-based medtech company Medopad has acquired Silicon Valley AI startup Sherbit in order to accelerate its ongoing expansion into the US market.
The terms of the acquisition have not been disclosed.
Medopad's ambitious aim is to "create a world where people can live longer." Its technology can connect patients with healthcare professionals, who can analyze a full range of data and, potentially, detect serious issues or life-threatening conditions and, once the diagnosis is complete, suggest any relevant course of action.
The company has partnered with some of the world's largest tech giants, including Apple and China-based Tencent, as well as large healthcare providers and pharmaceutical companies, to improve monitoring of rare, chronic diseases and conditions. It is also working with the Royal Free Hospital -- which had previously partnered with DeepMind -- Guy's, St Thomas' and Barts, among others, and is working on projects in China, Germany and Singapore. (See DeepMind NHS Deal Breached Data Protection Laws, Says ICO.)
Medopad CEO and Founder Dan Vahdat said: "At Medopad we want to create a world where people can live longer. We are working with some of the biggest companies in the world to improve the way doctors care for their patients by monitoring them at home and spotting any complications before they arise. We are expanding rapidly across the world and acquiring Sherbit is just the first step for us in the US."
Alex Senemar (left), CEO of Sherbit and Dan Vahdat (right), CEO of Medopad. (Image: Medopad)
He continued: "Sherbit has a strong track record of success working with some of the most prestigious healthcare organizations in the US, including the Mayo Clinic, Tufts Medical Center and Jefferson Health. Through this acquisition, Medopad will provide its technology to support solutions across different disease areas, from rare diseases to chronic conditions."
Sherbit, meanwhile, is working with major US healthcare providers to improve the care and treatment of patients with chronic illnesses by using artificial intelligence.
Sherbit CEO Alex Senemar commented on the acquisition: "Sherbit and Medopad have the same vision -- to help people be healthier and live longer. We're excited to leverage Medopad's technology, clinical, and predictive analytics capabilities to expand what's possible for our customers."